Rankings
▼
Calendar
FATE Q3 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FATE
Fate Therapeutics, Inc.
$158M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
+58.1% YoY
Gross Profit
$3M
100.0% margin
Operating Income
-$52M
-1703.9% margin
Net Income
-$48M
-1551.0% margin
EPS (Diluted)
$-0.40
QoQ Revenue Growth
-54.6%
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$30M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$495M
Total Liabilities
$133M
Stockholders' Equity
$362M
Cash & Equivalents
$38M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$2M
+58.1%
Gross Profit
$3M
-$3M
+209.9%
Operating Income
-$52M
-$51M
-2.1%
Net Income
-$48M
-$45M
-5.6%
← FY 2024
All Quarters
Q4 2024 →